Avinash Phadke

Ensemble Therapeutics (United States) — United States

Medicine · Health Sciences

13h-index547citations60works1.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatitis C virus research(8), Porphyrin and Phthalocyanine Chemistry(8), Organoboron and organosilicon chemistry(7), Synthetic Organic Chemistry Methods(7), Boron Compounds in Chemistry(6)

Publications60 total

Abstract 2894: NTX-452: a non-covalent, potent, selective and highly efficacious WRN inhibitor with best-in-class potential for the treatment of MSI-H tumors
Cancer Research·2025· 3 cited
Development of a Scalable Process for the Synthesis of Cyclopropyl-Methyl-Proline with Complex Stereochemistry: A Key Building Block of Factor D Inhibitors
Organic Process Research & Development·2024· 1 cited
356 (PB344): Preclinical characterization of NTX-452, a potent, selective and highly efficacious WRN inhibitor for the treatment of MSI-H tumors
European Journal of Cancer·2024
Discovery and characterization of novel inhibitors of CTP synthase 1 (CTPS1) for the treatment of autoimmune and inflammatory disease
The Journal of Immunology·2023· 2 citedOpen Access
Development of a Commercial Process for Odalasvir
Organic Process Research & Development·2021· 20 cited
Ocular Pharmacokinetics and Safety of Suprachoroidal A01017, Small Molecule Complement Inhibitor, Injectable Suspension in Rabbits
Investigative Ophthalmology & Visual Science·2020· 9 citedOpen Access
Ferrocene-based inhibitors of hepatitis C virus replication that target NS5A with low picomolar in vitro antiviral activity
Bioorganic & Medicinal Chemistry Letters·2018· 12 cited
Evaluation of mechanisms of paroxysm in paroxysmal nocturnal hemoglobinuria: In vitro explorations of “bystander” hemolysis and of perturbations of soluble regulators
Molecular Immunology·2017
Evaluation of risk of bacteria-mediated putative “bystander” hemolysis of PNH red blood cells in vitro : No evidence of significant complement-mediated hemolysis induced by microorganisms
Molecular Immunology·2017
Inhibition of complement alternative pathway by ACH-4471, the first clinical investigational orally-administered inhibitor of complement factor D
Molecular Immunology·2017· 1 cited
Comparison of complement functional assays: Differential sensitivities of hemolysis and Wieslab assays to levels of complement proteins C5, factor B, and factor D
Immunobiology·2016· 1 cited
Assessment of complement-mediated bacterial killing and the effect of a small molecule factor D inhibitor in vitro
Immunobiology·2016
Preclinical Evaluation of Orally Bioavailable Small-Molecule Inhibitors of Complement Factor D As a Potential Treatment for Paroxysmal Nocturnal Hemoglobinuria
Blood·2014· 6 cited
Novel Small-Molecule Inhibitors Targeting Complement Factor D for Therapy of Paroxysmal Nocturnal Hemoglobinuria
Blood·2014· 8 cited
ACH-806, an NS4A Antagonist, Inhibits Hepatitis C Virus Replication by Altering the Composition of Viral Replication Complexes
Antimicrobial Agents and Chemotherapy·2013· 11 citedOpen Access
845 PRECLINICAL CHARACTERISTICS OF ACH-3102: A NOVEL HCV NS5A INHIBITOR WITH IMPROVED POTENCY AGAINST GENOTYPE-1A VIRUS AND VARIANTS RESISTANT TO 1ST GENERATION OF NS5A INHIBITORS
Journal of Hepatology·2012· 18 cited
Selenophene-Containing Inhibitors of Type IIA Bacterial Topoisomerases
Journal of Medicinal Chemistry·2011· 55 citedOpen Access
1212 ACH-2928: A NOVEL HIGHLY POTENT HCV NS5A INHIBITOR WITH FAVORABLE PRECLINICAL CHARACTERISTICS
Journal of Hepatology·2011· 9 cited
650 ANTIVIRAL ACTIVITY, COMBINATION AND RESISTANCE OF ACH-1625, A POTENT, CLINICAL STAGE HCV NS3 PROTEASE INHIBITOR
Journal of Hepatology·2010· 3 cited
770 CHARACTERIZATION OF THE HEPATOSELECTIVE DISTRIBUTION OF ACH-1625, A POTENT, CLINICAL STAGE HCV NS3 PROTEASE INHIBITOR
Journal of Hepatology·2010· 4 cited
page 1 of 3Next →

Frequent Co-authors

Milind Deshpande(17), Mingjun Huang(15), Jason A. Wiles(13), Wengang Yang(11), J. Fabrycki(11), Atul Agarwal(9), Steven D. Podos(9), Jane A. Thanassi(8), Yongsen Zhao(8), Herbert C. Brown(8), M. V. RANGAISHENVI(8), Christopher W. Marlor(7), S. N. KULKARNI(7), Venkat R. Gadhachanda(6), Godwin C. G. Pais(5), Dharaben Patel(5), Xingtie Nie(4), Akihiro Hashimoto(4), K. Stauber(4), Guangwei Yang(4)